Drug profile · INN
respiratory syncytial virus rna vaccine
MRESVIA
respiratory syncytial virus rna vaccine (MRESVIA) is a fusion glycoprotein f0 vaccine antigen.
PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — respiratory syncytial virus rna vaccine
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
respiratory syncytial virus rna vaccine (MRESVIA) is a fusion glycoprotein f0 vaccine antigen.
Key facts
INN respiratory syncytial virus rna vaccine
Brand MRESVIA
Mechanism Fusion glycoprotein F0 vaccine antigen
Target Fusion glycoprotein F0
Mechanism of action
Fusion glycoprotein F0 vaccine antigen
Primary target: Fusion glycoprotein F0
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is respiratory syncytial virus rna vaccine?
respiratory syncytial virus rna vaccine (MRESVIA) is a fusion glycoprotein f0 vaccine antigen.
What is the brand name for respiratory syncytial virus rna vaccine?
MRESVIA is a marketed brand name for respiratory syncytial virus rna vaccine. Check FDA Drugs@FDA for the current US label holder and prescribing information.